Contract research (funded by Cynata Therapeutics Ltd; Armadale, Victoria) to determine the efficacy of Cynata-mesenchymal stem cells (MSCs) as a novel treatment for asthma, in comparison to or combined with a clinically-used corticosteroid (representing current standard of care for asthmatics).
|Short title||Evaluting the efficacy of Cynata-MSCs as a novel therapy for asthma|
|Effective start/end date||1/02/17 → 31/01/18|
- Allergic airways disease
- Airway remodelling
- Stem Cells